Last reviewed 2026-05-26 · How we verify

Test Product HY07121

Sichuan Huiyu Pharmaceutical Co., Ltd · Phase 1 active Small molecule ✓ Verified May 2026

Test Product HY07121 is a Small molecule drug developed by Sichuan Huiyu Pharmaceutical Co., Ltd. It is currently in Phase 1 development. Also known as: HY0007-101.

Test Product HY07121 is a small molecule being studied in a Phase 1/2 clinical trial for its safety, tolerability, and efficacy in patients with advanced solid tumors. The trial is being conducted by Sichuan Huiyu Pharmaceutical Co., Ltd.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Test Product HY07121
Also known as	HY0007-101
Sponsor	Sichuan Huiyu Pharmaceutical Co., Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Test Product HY07121 CI brief — competitive landscape report
Test Product HY07121 updates RSS · CI watch RSS
Sichuan Huiyu Pharmaceutical Co., Ltd portfolio CI

Frequently asked questions about Test Product HY07121

What is Test Product HY07121?

Test Product HY07121 is a Small molecule drug developed by Sichuan Huiyu Pharmaceutical Co., Ltd.

Who makes Test Product HY07121?

Test Product HY07121 is developed by Sichuan Huiyu Pharmaceutical Co., Ltd (see full Sichuan Huiyu Pharmaceutical Co., Ltd pipeline at /company/sichuan-huiyu-pharmaceutical-co-ltd).

Is Test Product HY07121 also known as anything else?

Test Product HY07121 is also known as HY0007-101.

What development phase is Test Product HY07121 in?

Test Product HY07121 is in Phase 1.

Manufacturer: Sichuan Huiyu Pharmaceutical Co., Ltd — full pipeline
Also known as: HY0007-101

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing